Literature DB >> 2810330

Synthesis of methotrexate-antibody conjugates by regiospecific coupling and assessment of drug and antitumor activities.

J Kralovec1, G Spencer, A H Blair, M Mammen, M Singh, T Ghose.   

Abstract

In order to increase the retention of drug activity, regiospecific coupling has been used to synthesize conjugates of methotrexate (MTX, 1) with normal rabbit IgG (NRG) and a mouse anti-human renal cancer monoclonal IgG (Dal K-20). MTX gamma-methyl ester (4) was produced either by selective esterification of MTX or by coupling of 4-amino-4-deoxy-N10-methylpteroic acid (2) with suitable glutamic acid derivatives. The MTX gamma-methyl ester (4) was then converted to the corresponding hydrazide 6. An amide-linked conjugate was formed when the MTX gamma-hydrazide (6) was converted to reactive acylating species 7 by using tert-butyl nitrite or trifluoroacetaldehyde, which were reacted with nucleophilic centers, presumably epsilon-amino groups, in native IgG. A hydrazone-linked conjugate was formed when MTX gamma-hydrazide (6) was reacted directly with IgG that had first been oxidized with periodate to form polyaldehyde IgG. The regiospecifically synthesized conjugates were somewhat more effective inhibitors in vitro of dihydrofolate reductase and of colony formation by human renal cancer (Caki-1) cells than were control nonregiospecific conjugates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2810330     DOI: 10.1021/jm00131a003

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier.

Authors:  P M Friden; L R Walus; G F Musso; M A Taylor; B Malfroy; R M Starzyk
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

Review 2.  Breast cancer: insights in disease and influence of drug methotrexate.

Authors:  Vítor Yang; Maria João Gouveia; Joana Santos; Beate Koksch; Irina Amorim; Fátima Gärtner; Nuno Vale
Journal:  RSC Med Chem       Date:  2020-05-28

3.  A quantitative assessment of nanoparticle-ligand distributions: implications for targeted drug and imaging delivery in dendrimer conjugates.

Authors:  Douglas G Mullen; Ming Fang; Ankur Desai; James R Baker; Bradford G Orr; Mark M Banaszak Holl
Journal:  ACS Nano       Date:  2010-02-23       Impact factor: 15.881

4.  Selective coupling of methotrexate to peptide hormone carriers through a gamma-carboxamide linkage of its glutamic acid moiety: benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate activation in salt coupling.

Authors:  A Nagy; B Szoke; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues.

Authors:  B Ballou; R Jaffe; S Persiani; W C Shen; J J Langone; H Sands; J M Reilandu; J Curley; T R Hakala
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

6.  Regression of human melanoma xenografts in nude mice injected with methotrexate linked to monoclonal antibody 225.28 to human high molecular weight-melanoma associated antigen.

Authors:  T Ghose; S Ferrone; A H Blair; Y Kralovec; M Temponi; M Singh; M Mammen
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

7.  Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma.

Authors:  S R Milovanovic; E Monje; K Szepeshazi; S Radulovic; A Schally
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

8.  Activation of methotrexate-phenylalanine by monoclonal antibody--carboxypeptidase A conjugate for the specific treatment of ovarian cancer in vitro.

Authors:  M J Perron; M Page
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.